celiprolol has been researched along with Insulin Resistance in 7 studies
Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of celiprolol on insulin sensitivity, glucose tolerance and serum lipids were compared to those of other antihypertensive drugs (beta- or Ca-blocker or ACE-inhibitor) in 23 dyslipidemic non-diabetic patients with controlled hypertension." | 9.08 | Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension. ( Huupponen, R; Lahtela, JT; Malminiemi, K, 1995) |
| "The effects of a vasodilating beta-blocker, celiprolol, on insulin sensitivity and cardiovascular risk factors were compared with those of another beta1-selective adrenoceptor blocker, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors." | 9.08 | Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents. ( Ala-Kaila, K; Huupponen, R; Lahtela, J; Malminiemi, K; Malminiemi, O, 1998) |
| " We investigated the influence of celiprolol, a beta 1-blocker with beta 2-agonistic and, possibly, additional weak alpha-receptor antagonistic properties, on insulin sensitivity (SI), glucose homeostasis, and lipid profile in 20 young, healthy, normotensive individuals." | 9.07 | Insulin sensitivity and atrial natriuretic factor during beta-receptor modulation with celiprolol in normal subjects. ( Böhlen, LM; de Courten, M; Hafezi, F; Riesen, W; Shaw, S; Weidmann, P, 1994) |
| "Impaired insulin sensitivity has been linked with chronic heart failure (CHF)." | 6.69 | Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure. ( Huupponen, R; Malminiemi, K; Pere, E; Pietilä, M; Pulkki, K; Rouru, J; Voipio-Pulkki, LM, 2000) |
| "Celiprolol is a beta 1-selective adrenoceptor antagonist with partial agonist activity at the beta 2-receptor as well as vasodilator properties." | 6.68 | Acute effects of celiprolol on muscle blood flow and insulin sensitivity: studies using [15O]-water, [18F]-fluorodeoxyglucose and positron emission tomography. ( Haaparanta, M; Knuuti, MJ; Laine, H; Malminiemi, K; Nuutila, P; Oikonen, V; Ruotsalainen, U, 1997) |
| "Metoprolol was without significant effect on any of these variables following chronic administration." | 5.30 | The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats. ( Dietze, GJ; Fogt, DL; Henriksen, EJ; Jacob, S, 1999) |
| "The effects of celiprolol on insulin sensitivity, glucose tolerance and serum lipids were compared to those of other antihypertensive drugs (beta- or Ca-blocker or ACE-inhibitor) in 23 dyslipidemic non-diabetic patients with controlled hypertension." | 5.08 | Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension. ( Huupponen, R; Lahtela, JT; Malminiemi, K, 1995) |
| "The effects of a vasodilating beta-blocker, celiprolol, on insulin sensitivity and cardiovascular risk factors were compared with those of another beta1-selective adrenoceptor blocker, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors." | 5.08 | Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents. ( Ala-Kaila, K; Huupponen, R; Lahtela, J; Malminiemi, K; Malminiemi, O, 1998) |
| " We investigated the influence of celiprolol, a beta 1-blocker with beta 2-agonistic and, possibly, additional weak alpha-receptor antagonistic properties, on insulin sensitivity (SI), glucose homeostasis, and lipid profile in 20 young, healthy, normotensive individuals." | 5.07 | Insulin sensitivity and atrial natriuretic factor during beta-receptor modulation with celiprolol in normal subjects. ( Böhlen, LM; de Courten, M; Hafezi, F; Riesen, W; Shaw, S; Weidmann, P, 1994) |
| "Impaired insulin sensitivity has been linked with chronic heart failure (CHF)." | 2.69 | Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure. ( Huupponen, R; Malminiemi, K; Pere, E; Pietilä, M; Pulkki, K; Rouru, J; Voipio-Pulkki, LM, 2000) |
| "Celiprolol is a beta 1-selective adrenoceptor antagonist with partial agonist activity at the beta 2-receptor as well as vasodilator properties." | 2.68 | Acute effects of celiprolol on muscle blood flow and insulin sensitivity: studies using [15O]-water, [18F]-fluorodeoxyglucose and positron emission tomography. ( Haaparanta, M; Knuuti, MJ; Laine, H; Malminiemi, K; Nuutila, P; Oikonen, V; Ruotsalainen, U, 1997) |
| "Metoprolol was without significant effect on any of these variables following chronic administration." | 1.30 | The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats. ( Dietze, GJ; Fogt, DL; Henriksen, EJ; Jacob, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böhlen, LM | 1 |
| de Courten, M | 1 |
| Hafezi, F | 1 |
| Shaw, S | 1 |
| Riesen, W | 1 |
| Weidmann, P | 1 |
| Malminiemi, K | 5 |
| Lahtela, JT | 1 |
| Huupponen, R | 3 |
| Laine, H | 1 |
| Knuuti, MJ | 1 |
| Ruotsalainen, U | 1 |
| Oikonen, V | 1 |
| Haaparanta, M | 1 |
| Nuutila, P | 1 |
| Lahtela, J | 1 |
| Malminiemi, O | 1 |
| Ala-Kaila, K | 1 |
| Jacob, S | 1 |
| Fogt, DL | 1 |
| Dietze, GJ | 1 |
| Henriksen, EJ | 1 |
| Pietilä, M | 1 |
| Rouru, J | 1 |
| Pulkki, K | 1 |
| Pere, E | 1 |
| Voipio-Pulkki, LM | 1 |
6 trials available for celiprolol and Insulin Resistance
| Article | Year |
|---|---|
Insulin sensitivity and atrial natriuretic factor during beta-receptor modulation with celiprolol in normal subjects.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Atrial Natriuretic Facto | 1994 |
Effects of celiprolol on insulin sensitivity and glucose tolerance in dyslipidemic hypertension.
Topics: Adult; Blood Glucose; Blood Pressure; Celiprolol; Female; Glucose Clamp Technique; Glucose Tolerance | 1995 |
Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Glucose; Blood Pressure; Celiprolol; Dru | 1995 |
Acute effects of celiprolol on muscle blood flow and insulin sensitivity: studies using [15O]-water, [18F]-fluorodeoxyglucose and positron emission tomography.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Celiprolol; Cross-Over S | 1997 |
Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Celiprolol; Cross-Over Studies; Double-Blind Me | 1998 |
Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Celiprolol; Cholesterol, HDL; Cholesterol, LDL; Exercise; Female; Heart | 2000 |
1 other study available for celiprolol and Insulin Resistance
| Article | Year |
|---|---|
The beta2-adrenergic modulator celiprolol reduces insulin resistance in obese Zucker rats.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Biological Transport, Active; Blood G | 1999 |